Randomized Safety, Tolerability and Pilot Efficacy of AN-1792 in Alzheimer's Disease

Lead sponsor

JANSSEN Alzheimer Immunotherapy Research & Development, LLC

Asset

AN-1792

Listed sites

Recruiting sites

Enrollment

375

Study population

Alzheimer’s disease

Key I/E criterion

•mild-to-moderate AD

Primary endpoint

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

Org study IDAN-1792-201

NCT IDNCT00021723

Timeline

Milestones

Study first posted2001-08-06estimated

Study start2001-09 (month precision)

Study completion2003-09 (month precision)

Last update posted2009-09-24estimated

Assets

Drug assets

AN-1792

Study populations

Who this study enrolls

Alzheimer’s disease

Eligibility

Who can enroll

Minimum age50 Years

Maximum age85 Years

SexAll

Healthy volunteersNot accepted

Eligibility criteria

Mild to moderate Alzheimer's disease. Ability to cooperate with MRI scanning and neuropsychological testing. Live at home or in the community and a caregiver capable of accompanying the patient on all clinic visits and visiting the patient at least 5 times per week.

Endpoints (0)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

No endpoints recorded for this trial.

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 21, 2026

Endpoint classificationDelfa ADRD endpoint taxonomy

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.